Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer.

[1]  J. Doorbar.  The human Papillomavirus twilight zone – Latency, immune control and subclinical infection , 2023, Tumour virus research.

[2]  S. Regauer,et al.  Elimination of reserve cells for prevention of HPV-associated cervical cancer , 2023, Virus research.

[3]  M. Reuschenbach,et al.  Human Papillomavirus Vaccine Impact and Effectiveness in Six High-Risk Populations: A Systematic Literature Review , 2022, Vaccines.

[4]  J. Dillner,et al.  Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis , 2022, BMJ.

[5]  P. Lukeš,et al.  Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial. , 2022, JAMA otolaryngology-- head & neck surgery.

[6]  J. Ordi,et al.  HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions , 2022, Vaccines.

[7]  W. Quint,et al.  Evidence of latent HPV infection in older Danish women with a previous history of cervical dysplasia , 2022, Acta obstetricia et gynecologica Scandinavica.

[8]  P. T. Jensen,et al.  Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta‐analysis , 2022, Acta obstetricia et gynecologica Scandinavica.

[9]  I. Zapardiel,et al.  Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study , 2022, Vaccines.

[10]  Ke-Jia Zheng,et al.  Role of E6 in Maintaining the Basal Cell Reservoir during Productive Papillomavirus Infection , 2022, Journal of virology.

[11]  A. Sarro,et al.  Could the human papillomavirus recombinant vaccine be a new valid approach in the management of ano-genital warts? , 2021, Annali di igiene : medicina preventiva e di comunita.

[12]  W. Tjalma,et al.  If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment? , 2021, European journal of obstetrics, gynecology, and reproductive biology.

[13]  Yuwen Chen,et al.  Principles of epithelial homeostasis control during persistent human papillomavirus infection and its deregulation at the cervical transformation zone. , 2021, Current opinion in virology.

[14]  Y. Qiao,et al.  Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study , 2021, The Lancet regional health. Western Pacific.

[15]  W. Quint,et al.  HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM , 2021, AIDS.

[16]  E. Kontopantelis,et al.  Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis , 2021, Vaccines.

[17]  G. Bogani,et al.  Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease , 2021, Vaccines.

[18]  R. Crawford,et al.  Dynamics of papillomavirus in vivo disease formation & susceptibility to high-level disinfection-Implications for transmission in clinical settings. , 2021, EBioMedicine.

[19]  A. Dell'Acqua,et al.  Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison , 2020, Vaccines.

[20]  S. Rosso,et al.  Risk of HPV-related extra-cervical cancers in women treated for cervical intraepithelial neoplasia , 2020, BMC cancer.

[21]  P. Michelow,et al.  HPV Vaccination Prior to Loop Electroexcision Procedure does not Prevent Recurrent Cervical High Grade Squamous Intraepithelial Lesions in Women Living with HIV: a Randomized, Double-blind, Placebo-controlled Trial. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Dell'Acqua,et al.  Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study. , 2020, Gynecologic oncology.

[23]  A. Youk,et al.  Rates of new human papillomavirus detection and loss of detection in middle-aged women by recent and past sexual behavior. , 2020, The Journal of infectious diseases.

[24]  M. Jit,et al.  Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. , 2020, Health technology assessment.

[25]  D. Gallardo-Rincón,et al.  THERAPEUTIC USE OF HUMAN PAPILLOMAVIRUS VACCINES IN CERVICAL LESIONS. , 2020, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[26]  P. Hillemanns,et al.  Prophylactic HPV vaccination after conization: A systematic review and meta-analysis , 2020, Geburtshilfe und Frauenheilkunde.

[27]  L. Mariani,et al.  Extending Human Papillomavirus (HPV) vaccination beyond female adolescents and after treatment for high grade CIN: the Italian HPV Study Group (IHSG) review and position paper. , 2020, European review for medical and pharmacological sciences.

[28]  S. Polinder,et al.  Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial , 2020, BMC Cancer.

[29]  J. Ordi,et al.  HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions , 2020, Vaccines.

[30]  A. Rogers,et al.  Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis , 2020, International Journal of Gynecological Cancer.

[31]  K. Levinson,et al.  Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. , 2020, Obstetrics and gynecology.

[32]  R. Kirsner,et al.  Systemic and intratumoral 9-valent human papillomavirus vaccine treatment for squamous cell carcinoma in situ in a renal transplant recipient , 2020, JAAD case reports.

[33]  I. Alkatout,et al.  Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial , 2020, BMC Public Health.

[34]  M. Capobianchi,et al.  The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease , 2020, Frontiers in Immunology.

[35]  G. Gupta,et al.  Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Salanti,et al.  Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  K. Makiyama,et al.  Multi‐Year Effect of Human Papillomavirus Vaccination on Recurrent Respiratory Papillomatosis , 2020, The Laryngoscope.

[38]  A. Cossu,et al.  Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution’s Experience , 2020, Vaccines.

[39]  Rita Kundu,et al.  Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy , 2020, Frontiers in Microbiology.

[40]  S. Kjaer,et al.  Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status , 2019, International journal of cancer.

[41]  P. van Damme,et al.  HPV vaccination, are we overlooking additional opportunities to control HPV infection and transmission? , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[42]  P. Szilagyi,et al.  Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices , 2019, MMWR. Morbidity and mortality weekly report.

[43]  A. Giuliano,et al.  Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. , 2019, Gynecologic oncology.

[44]  A. Wald,et al.  Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA) , 2019, JAMA network open.

[45]  Hoon Choi.  Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study , 2019, International braz j urol : official journal of the Brazilian Society of Urology.

[46]  W. Quint,et al.  Whole tissue cervical mapping of HPV infection: Molecular evidence for focal latent HPV infection in humans , 2019, Papillomavirus research.

[47]  N. Borruel,et al.  Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[48]  L. Matrka,et al.  Implementation of Routine HPV Vaccination in the Management of Recurrent Respiratory Papillomatosis , 2018, The Annals of otology, rhinology, and laryngology.

[49]  Young Nam Kim,et al.  Persistent HPV-16 infection leads to recurrence of high-grade cervical intraepithelial neoplasia , 2018, Medicine.

[50]  C. Godballe,et al.  Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis , 2018, The Journal of infectious diseases.

[51]  F. Petraglia,et al.  Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease , 2018, Archives of Gynecology and Obstetrics.

[52]  N. Muñoz,et al.  Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58 , 2018, JNCI cancer spectrum.

[53]  F. Parazzini,et al.  SPERANZA project: HPV vaccination after treatment for CIN2. , 2018, Gynecologic oncology.

[54]  C. Huang,et al.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. , 2018, Human gene therapy.

[55]  T. Iftner,et al.  HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis , 2018, BMC Infectious Diseases.

[56]  M. Ingersoll,et al.  Mechanisms of BCG immunotherapy and its outlook for bladder cancer , 2018, Nature Reviews Urology.

[57]  K. Mackenzie,et al.  A retrospective case‐control analysis of the efficacy of Gardasil® vaccination in 28 patients with recurrent respiratory papillomatosis of the larynx , 2018, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[58]  P. Stern,et al.  Opportunities and challenges for human papillomavirus vaccination in cancer , 2018, Nature Reviews Cancer.

[59]  S. Leeson,et al.  Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. , 2017, The Lancet. Oncology.

[60]  E. Moeller,et al.  9-Valent human papillomavirus vaccine: a review of the clinical development program , 2017, Expert review of vaccines.

[61]  R. Winer,et al.  Natural History of HPV Infection across the Lifespan: Role of Viral Latency , 2017, Viruses.

[62]  J. Chhatwal,et al.  Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now. , 2017, Vaccine.

[63]  J. Doorbar.  Host control of human papillomavirus infection and disease. , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[64]  M. Plummer,et al.  Worldwide burden of cancer attributable to HPV by site, country and HPV type , 2017, International journal of cancer.

[65]  H. Sudhoff,et al.  Recurrent respiratory papillomatosis (RRP)–time for a reckoning? , 2017, Laryngoscope investigative otolaryngology.

[66]  W. Melchers,et al.  Long-Lasting Increased Risk of Human Papillomavirus-Related Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia Grade 3: A Population-Based Cohort Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Nicolas Wentzensen,et al.  Carcinogenic human papillomavirus infection , 2016, Nature Reviews Disease Primers.

[68]  M. Lehtinen,et al.  Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial , 2016, International journal of cancer.

[69]  N. Trinklein,et al.  A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects , 2016, EBioMedicine.

[70]  E. R. van den Heuvel,et al.  Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis , 2016, European Archives of Oto-Rhino-Laryngology.

[71]  L. Weckx,et al.  Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. , 2016, International journal of pediatric otorhinolaryngology.

[72]  V. Adámková,et al.  Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: Population-based cross-sectional survey of Czech women aged 16 to 40 years. , 2015, Vaccine.

[73]  K. Egawa,et al.  Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia , 2015, Viruses.

[74]  A. Giuliano,et al.  Seroconversion following anal and genital HPV infection in men: The HIM study , 2015, Papillomavirus research.

[75]  W. Quint,et al.  Stratification of HPV-Induced Cervical Pathology using the Virally-Encoded Molecular Marker E4 in Combination with p16 or MCM , 2015, Modern Pathology.

[76]  L. Halstead,et al.  The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. , 2015, Journal of voice : official journal of the Voice Foundation.

[77]  O. Dillioglugil,et al.  Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study. , 2014, The journal of sexual medicine.

[78]  Kristin A. Swedish,et al.  Prevention of Anal Condyloma with Quadrivalent Human Papillomavirus Vaccination of Older Men Who Have Sex with Men , 2014, PloS one.

[79]  B. Trus,et al.  The papillomavirus major capsid protein L1. , 2013, Virology.

[80]  J. Doorbar.  The E4 protein; structure, function and patterns of expression. , 2013, Virology.

[81]  W. Kang,et al.  Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? , 2013, Gynecologic oncology.

[82]  J. Doorbar.  Latent papillomavirus infections and their regulation. , 2013, Current opinion in virology.

[83]  David J. Breland,et al.  Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. , 2013, The Journal of infectious diseases.

[84]  S. Wacholder,et al.  HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays , 2013, PloS one.

[85]  M. Hibma.  The Immune Response to Papillomavirus During Infection Persistence and Regression , 2012, The open virology journal.

[86]  W. Quint,et al.  E4 Antibodies Facilitate Detection and Type-Assignment of Active HPV Infection in Cervical Disease , 2012, PloS one.

[87]  Wim Quint,et al.  The biology and life-cycle of human papillomaviruses. , 2012, Vaccine.

[88]  M. Schiffman,et al.  Updating the natural history of human papillomavirus and anogenital cancers. , 2012, Vaccine.

[89]  S. Garland,et al.  A review of clinical trials of human papillomavirus prophylactic vaccines. , 2012, Vaccine.

[90]  M. Stanley.  Epithelial Cell Responses to Infection with Human Papillomavirus , 2012, Clinical Microbiology Reviews.

[91]  S. Factor,et al.  Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[92]  Daron G Ferris,et al.  Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data , 2012, BMJ : British Medical Journal.

[93]  A. Giuliano,et al.  Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. , 2012, Cancer research.

[94]  C. Wheeler,et al.  Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection , 2011, International journal of cancer.

[95]  N. Muñoz,et al.  End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age , 2011, British Journal of Cancer.

[96]  A. Giuliano,et al.  Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study , 2011, The Lancet.

[97]  S. Wacholder,et al.  Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. , 2010, Journal of the National Cancer Institute.

[98]  J. Schiller,et al.  Current understanding of the mechanism of HPV infection. , 2010, Gynecologic oncology.

[99]  A. Saah,et al.  Prevalence and Incidence of HPV Genital Infection in Women , 2009, Sexually transmitted diseases.

[100]  C. Wheeler,et al.  Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection , 2009, Human vaccines.

[101]  E. Unger,et al.  Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. , 2009, The Journal of infectious diseases.

[102]  R. Railkar,et al.  Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. , 2009, The Journal of infectious diseases.

[103]  W. Melchers,et al.  High‐risk HPV presence in cervical specimens after a large loop excision of the cervical transformation zone: Significance of newly detected hr‐HPV genotypes , 2007, Journal of medical virology.

[104]  J. Hogan,et al.  Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[105]  J. Arends,et al.  Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell. , 2004, Anticancer research.

[106]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.

[107]  C. Arens,et al.  Treatment outcomes of recurrent respiratory papillomatosis , 2017, HNO.